Evidence map›Paper›PMID 39541163›Full record

ArticleJCI insight2024

Profound reduction of HIV-1 reservoir cells over 3 decades of antiretroviral therapy started in early infancy.

Liliana C Vela, Leah Carrere, Chloe Naasz, Sruthi Kalavacherla, Toong Seng Tan, Lesley de Armas, Ce Gao, Xu G Yu, Savita G Pahwa, Katherine Luzuriaga and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liliana C VelaRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Leah CarrereRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Chloe NaaszRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Sruthi KalavacherlaRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Toong Seng TanRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Lesley de ArmasDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Ce GaoRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Savita G PahwaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Katherine LuzuriagaProgram in Molecular Medicine, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, USA.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.

Funding

University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Rana Chakraborty · 2007 to 2026
$33.8M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Miami MACS-WIHS Combined Cohort Study Clinical Research SiteU01HL146203 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE, Deborah Lynne Jones · 2019 to 2026
$21.2M
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4M
Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccinesU01AI135941 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI PALMA, PAOLO, ROBB, MERLIN L · 2018 to 2024
$6.4M
Elite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2M
Immune Dysfunction in HIV+ Opioid UsersR01DA051202 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI PAHWA, SAVITA · 2020 to 2025
$4.6M
Single-cell Proteogenomic profiling of HIV-1 reservoir cellsR01AI176579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2023 to 2026
$4.6M
Gates Foundation INV-002703NCATS NIH HHS UL1 TR001453NHLBI NIH HHS R01 HL134539NHLBI NIH HHS U01 HL146203NIAID NIH HHS K24 AI155233NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI142669NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI155171NIAID NIH HHS U01 AI135940NIAID NIH HHS U01 AI135941NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIA NIH HHS R01 AG068110NIDA NIH HHS R01 DA051202NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIDDK NIH HHS R01 DK120387NIMH NIH HHS R01 MH134823
6 · The paper itself

Abstract

HIV-1 reservoir cells persist indefinitely during suppressive antiretroviral therapy (ART) in individuals who acquire infection in adulthood, but little is known about the longitudinal evolution of viral reservoir cells during long-term ART started during early infancy. We studied 2 fraternal twins who acquired HIV-1 perinatally, started ART at week 10 after birth and remained on ART for 28 years. We observed that the frequency of genome-intact proviruses, determined by single-genome near-full-length proviral sequencing, declined by approximately 4,000- to 13,000-fold during this period, indicating enhanced decay rates of intact proviruses even after adjusting for dilution effects from somatic growth. Despite analyzing more than one billion PBMC after 28 years of ART in each participant, no intact proviruses were detected in 1 participant, and 1 intact provirus was isolated in the other. The longitudinal decline of defective proviruses in the 2 participants was more similar to proviral decay kinetics reported in individuals who started ART during adulthood; moreover, clonal sequence clusters were readily detectable for defective proviruses but not for intact proviruses after 28 years of ART in the 2 twins. Together, these data suggest decreased long-term stability and increased immunological vulnerability of intact proviruses during long-term ART started in early infancy.

Indexed as

HIV-1HIV InfectionsProvirusesViral LoadAdultAnti-HIV AgentsAnti-Retroviral AgentsCD4-Positive T-LymphocytesFemaleHumansInfantInfant, NewbornMaleAnti-HIV AgentsAnti-Retroviral AgentsAdaptive immunityAIDS/HIVT cellsVirology

Identifiers

PMID39541163
PMCPMC11721289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.